Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 222

Similar articles for PubMed (Select 20303470)

1.

The lipid triad, or how to reduce residual cardiovascular risk?

Girard-Mauduit S.

Ann Endocrinol (Paris). 2010 Mar;71(2):89-94. doi: 10.1016/j.ando.2010.02.001. Epub 2010 Mar 19.

PMID:
20303470
3.

"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2010 Jun 15;9:24. doi: 10.1186/1475-2840-9-24.

4.
5.

Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.

Van Ganse E, Laforest L, Burke T, Phatak H, Souchet T.

Clin Ther. 2007 Aug;29(8):1671-81.

PMID:
17919548
6.

Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum.

Ascaso J, Gonzalez Santos P, Hernandez Mijares A, Mangas Rojas A, Masana L, Millan J, Pallardo LF, Pedro-Botet J, Perez Jimenez F, Pintó X, Plaza I, Rubiés J, Zúñiga M.

Am J Cardiovasc Drugs. 2007;7(1):39-58. Review. Erratum in: Am J Cardiovasc Drugs. 2007;7(4):302.

PMID:
17355165
7.

Dyslipidaemia, hypercoagulability and the metabolic syndrome.

Kakafika AI, Liberopoulos EN, Karagiannis A, Athyros VG, Mikhailidis DP.

Curr Vasc Pharmacol. 2006 Jul;4(3):175-83. Review.

PMID:
16842135
8.

Cardiovascular disease risk of type 2 diabetes mellitus and metabolic syndrome: focus on aggressive management of dyslipidemia.

Falko JM, Moser RJ, Meis SB, Caulin-Glaser T.

Curr Diabetes Rev. 2005 May;1(2):127-35. Review.

PMID:
18220588
9.

Role for fibrate therapy in diabetes: evidence before FIELD.

Vergès B.

Curr Opin Lipidol. 2005 Dec;16(6):648-51. Review.

PMID:
16276243
10.

High cardiovascular risk in patients with diabetes and the cardiometabolic syndrome: mandate for statin therapy.

Gonzalez GL, Manrique CM, Sowers JR.

J Cardiometab Syndr. 2006 Summer;1(3):178-83. Review.

PMID:
17679817
11.

Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.

Evans M, Roberts A, Davies S, Rees A.

Drugs. 2004;64(11):1181-96. Review.

PMID:
15161326
12.

Benefits of lipid-lowering therapy in patients with type 2 diabetes mellitus.

Betteridge J.

Am J Med. 2005 Dec;118 Suppl 12A:10-5.

PMID:
16356802
13.

What is the most effective strategy for managing diabetic dyslipidaemia?

Reasner CA.

Atheroscler Suppl. 2005 Sep;6(3):21-7. Review.

PMID:
16054442
14.

Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study.

Leiter LA, Lundman P, da Silva PM, Drexel H, Jünger C, Gitt AK; DYSIS investigators.

Diabet Med. 2011 Nov;28(11):1343-51. doi: 10.1111/j.1464-5491.2011.03360.x.

PMID:
21679231
15.
16.

[Dyslipemia in diabetics treated with statins. Results of the DYSIS study in Spian].

Millán J, Alegría E, Guijarro C, Lozano JV, Vitale GC, González-Timón B, González-Juanatey JR.

Med Clin (Barc). 2013 Nov 16;141(10):430-6. doi: 10.1016/j.medcli.2012.09.030. Epub 2012 Dec 12. Spanish.

PMID:
23246165
17.

[Pharmacological therapy of obesity].

Pagotto U, Vanuzzo D, Vicennati V, Pasquali R.

G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):83S-93S. Italian.

PMID:
18773755
18.
19.

Management of hypercholesterolaemia in the patient with diabetes.

Packard C, Olsson AG.

Int J Clin Pract Suppl. 2002 Jul;(130):27-32. Review.

PMID:
12296606
20.

Dyslipidemia in the metabolic syndrome in children.

Gidding SS.

J Cardiometab Syndr. 2006 Summer;1(4):282-5. Review.

PMID:
17679808
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk